RVU — Ryvu Therapeutics SA Share News
0.000.00%
Last trade - 00:00- PLN417.09m
- PLN434.44m
- PLN62.25m
Brief: Ryvu Therapeutics Says Its Project Recommended For Funding By Poland's PARP
Brief: Ryvu Therapeutics FY Net Loss Widens To 92.1 Mln Zlotys
Brief: Ryvu Therapeutics To Get EUR 8 Mln Of Financing From EIB
Brief: Ryvu Therapeutics Reaches Second Milestone Under License Agreement With Exelixis
Brief: Ryvu Therapeutics Q3 Net Loss Widens To 18.3 Mln Zlotys
Brief: Ryvu Therapeutics Sa Says Plan To Initiate Remark Study In First Half Of 2024
Brief: Ryvu Therapeutics Signs EUR 4 Mln Financial Support Deal For 'Remark' Study
Brief: Ryvu Therapeutics Q2 Net Loss Narrows To 28.5 Mln Zlotys
Ryvu and TIM to enter Warsaw's mWIG40 index
Brief: Ryvu Therapeutics Signs Two Service Deals For River-52 And River-81 Studies
Brief: Ryvu Therapeutics Signs Deal With Medical Research Agency For Up to 62.3 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Secures Supply Chain For River-81 Study For About EUR 3.9 Mln
Brief: Ryvu Therapeutics Signs Two Deals With Clinscience
Brief: Ryvu Therapeutics Signs Two Deals On RVU120
Brief: Ryvu Therapeutics Recommended For 62.3 Mln Zloty Subsidy For Clinical Trial Of RVU120
Brief: Ryvu Therapeutics Q1 Net Loss Narrows To 17.6 Mln Zlotys
Brief: Ryvu Therapeutics Signs EUR 1.2 Mln Deals With Labcourp Drug Development
Brief: Galapagos NV Ends R&D Deal With Ryvu Therapeutics
Brief: Ryvu Therapeutics FY Net Loss Widens To 83.8 Mln Zlotys